ONC

BeiGene, Ltd.

BeiGene, Ltd. (ONC) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C
Factor Score 2.2 / 5.0
Growth
B
Factor Score 3.3 / 5.0
Profitability
B+
Factor Score 3.6 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 73.1
EV / EBITDA 35.1
Rev Growth YoY 35.5%
Gross Margin 88.3%
Price Return 3M 8.7%
Price Return 12M 8.0%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 5.8
ROE 12.4%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C (2.2) B (3.3) B+ (3.6) C (2.4) C- (1.9) C+ (2.7)
2026-08-04 C (2.2) B (3.3) B+ (3.6) C (2.4) C- (1.9) C+ (2.7)
2026-08-03 C- (2.1) B- (3.1) B (3.4) C (2.4) C- (2.0) C+ (2.6)
2026-08-02 C- (2.1) B- (3.1) B (3.3) C (2.4) C- (1.9) C+ (2.6)